Johan M. Spoor, CEO and director of Perspective Therapeutics, Inc. (NASDAQ:CATX), recently purchased 8,000 shares of the company's common stock. The transaction, dated December 4, 2024, was executed at a weighted average price of approximately $3.7665 per share, resulting in a total investment of $30,132. The purchase comes as the stock trades near $3.71, having declined significantly over recent months, though InvestingPro data shows strong analyst support with a consensus Strong Buy rating.
Following this acquisition, Spoor now directly owns 36,257 shares of Perspective Therapeutics. In addition to his direct holdings, Spoor also has indirect ownership through various accounts, including 5,400 shares by his IRA, 12,600 shares by his spouse's IRA, and 1,000 shares by his child. The company, currently valued at $250 million, maintains a healthy balance sheet with a robust current ratio of 9.6 and more cash than debt.
This recent purchase underscores Spoor's ongoing commitment to the company, as he continues to expand his stake in the Seattle-based firm, which specializes in surgical and medical instruments and apparatus. According to InvestingPro, the stock appears undervalued, trading at just 0.76 times book value. Subscribers can access 12 additional ProTips and comprehensive analysis through the Pro Research Report.
In other recent news, Perspective Therapeutics has experienced a series of significant developments. RBC Capital adjusted its price target for the company to $16 from $25, while maintaining an Outperform rating. This adjustment followed the initial data from the ongoing VMT-α-NET Phase I/IIa study, which indicated promising signals but also the need for patience in dose optimization. BofA Securities downgraded the company's stock from a 'Buy' to a 'Neutral' rating due to challenges with the VMT-α-NET and VMT01 treatments.
On the other hand, UBS initiated coverage on Perspective Therapeutics' stock with a 'Buy' rating and a price target of $20.00, estimating that the VMT-α-NET program could achieve peak sales of $1.2 billion. Oppenheimer also maintained an 'Outperform' rating on the company's shares, following the presentation of updated data from an ongoing compassionate use study of VMT-α-NET.
Truist Securities maintained its 'Buy' rating and $21.00 price target for Perspective Therapeutics' stock, suggesting that the negative reaction to the melanoma data presents an opportunity for buyers. The firm estimates peak adjusted and unadjusted sales for the melanoma treatment could reach approximately $170 million and $850 million, respectively.
Lastly, Perspective Therapeutics announced changes in its executive roles and entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets. The company also announced plans to increase the number of participants in Cohort 2 of their VMT-α-NET study from 7 to 47.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.